Keros Therapeutics, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| OrbiMed Genesis GP LLC | — | Disposition | 74,465 | $17.75 | $1,321,754 | 45,057 | Nov 21, 2025 |
| GORDON CARL L | — | Disposition | 140,057 | $17.75 | $2,486,012 | 759,155 | Nov 21, 2025 |
| Knowles Julius | — | Disposition | 130,494 | $17.75 | $2,316,269 | 102,233 | Nov 21, 2025 |
| Pontifax (China) IV L.P. | — | Sale | 1,121,045 | $17.75 | $19,898,549 | — | Oct 15, 2025 |
| Schneeberger Daniel | — | Sale | 743,358 | $17.75 | $13,194,605 | — | Oct 15, 2025 |
| Seehra Jasbir | CHIEF EXECUTIVE OFFICER | Award / Grant | 90,500 | — | — | 392,723 | Sep 3, 2025 |
| Schneeberger Daniel | — | X | 200 | $70.00 | $14,000 | 743,358 | Jun 20, 2025 |
| Knowles Julius | — | Award / Grant | 5,250 | — | — | 6,441 | Jun 4, 2025 |
| GORDON CARL L | — | Award / Grant | 5,250 | — | — | 5,250 | Jun 4, 2025 |
| Kariv Tomer | — | Award / Grant | 5,250 | — | — | 5,250 | Jun 4, 2025 |
| Nussbaum Ran | — | Award / Grant | 5,250 | — | — | 5,250 | Jun 4, 2025 |
| Seth Alpna | — | Award / Grant | 5,250 | — | — | 5,250 | Jun 4, 2025 |
| GRAY MARY ANN | — | Award / Grant | 5,250 | — | — | 5,250 | Jun 4, 2025 |
| Farzan Nima | — | Award / Grant | 5,250 | — | — | 5,250 | Jun 4, 2025 |
| BIENAIME JEAN JACQUES | — | Award / Grant | 5,250 | — | — | 5,450 | Jun 4, 2025 |
| ADAR1 Partners, LP | — | Purchase | 74,333 | $10.33 | $767,860 | 4,392,737 | Apr 9, 2025 |
| Seehra Jasbir | CHIEF EXECUTIVE OFFICER | Option Exercise | 49,367 | $0.30 | $14,810 | 302,223 | Apr 4, 2025 |
| CHYUNG YUNG H. | Chief Medical Officer | Award / Grant | 44,000 | — | — | 44,000 | Feb 18, 2025 |
| Regnante Keith | CHIEF FINANCIAL OFFICER | Award / Grant | 44,000 | — | — | 44,000 | Feb 18, 2025 |
| Rovaldi Christopher | Chief Operating Officer | Award / Grant | 60,000 | — | — | 60,000 | Feb 18, 2025 |
| GORDON CARL L | — | Sale | 29,400 | $44.01 | $1,293,894 | 119,522 | Aug 13, 2024 |
| OrbiMed Genesis GP LLC | — | Sale | 220,600 | $44.01 | $9,708,606 | 899,212 | Aug 13, 2024 |
| Regnante Keith | CHIEF FINANCIAL OFFICER | Option Exercise | 40,000 | $16.00 | $640,000 | 40,000 | Jan 4, 2024 |
| Regnante Keith | Chief Financial Officer | Sale | 40,000 | $45.29 | $1,811,600 | — | Nov 4, 2023 |
| Regnante Keith | Chief Financial Officer | Option Exercise | 20,000 | $16.00 | $320,000 | 20,000 | Jun 9, 2023 |
| Seehra Jasbir | Chief Executive Officer | Option Exercise | 4,000 | $0.48 | $1,920 | 252,856 | Apr 8, 2023 |
| Pontifax Late Stage GP Ltd. | — | X | 1,723 | — | — | 1,121,045 | Nov 29, 2022 |
| Nussbaum Ran | — | X | 1,723 | — | — | 1,121,045 | Nov 29, 2022 |
| Kariv Tomer | — | X | 1,723 | — | — | 1,121,045 | Nov 29, 2022 |
| Lachey Jennifer | Chief Scientific Officer | Sale | 46,034 | $30.00 | $1,381,020 | 95,100 | Jul 15, 2022 |
| Lachey Jennifer | Chief Scientific Officer | Sale | 1,916 | $30.00 | $57,480 | 95,100 | Jul 13, 2022 |
| Lachey Jennifer | Chief Scientific Officer | Option Exercise | 9,400 | $0.30 | $2,820 | 95,100 | Jun 14, 2022 |
| Seehra Jasbir | Chief Executive Officer | Option Exercise | 5,000 | $0.30 | $1,500 | 248,856 | Jun 9, 2022 |
| Lachey Jennifer | Chief Scientific Officer | Sale | 16 | $45.45 | $727 | 85,700 | May 11, 2022 |
| Lachey Jennifer | Chief Scientific Officer | Option Exercise | 5,300 | $0.30 | $1,590 | 91,000 | Apr 11, 2022 |
| Rovaldi Christopher | Chief Operating Officer | Option Exercise | 1,728 | $16.00 | $27,648 | 1,728 | Apr 6, 2022 |
| Lachey Jennifer | Chief Scientific Officer | Sale | 7,950 | $60.00 | $477,000 | 85,700 | Apr 4, 2022 |
| Rovaldi Christopher | Chief Operating Officer | Sale | 105 | $58.83 | $6,177 | — | Apr 1, 2022 |
| Lachey Jennifer | Chief Scientific Officer | Sale | 875 | $54.54 | $47,723 | 85,700 | Mar 11, 2022 |
| Lachey Jennifer | Chief Scientific Officer | Sale | 1,378 | $52.35 | $72,138 | 85,899 | Feb 11, 2022 |
| Lachey Jennifer | Chief Scientific Officer | Sale | 320 | $52.01 | $16,643 | 88,030 | Jan 11, 2022 |
| Lachey Jennifer | Chief Scientific Officer | Sale | 2,650 | $60.00 | $159,000 | 85,700 | Jan 5, 2022 |
| Knowles Julius | — | Sale | 794 | $54.95 | $43,630 | 355,365 | Jan 4, 2022 |
| Lachey Jennifer | Chief Scientific Officer | Option Exercise | 1,915 | $0.30 | $575 | 87,615 | Dec 13, 2021 |
| Knowles Julius | — | Sale | 2,528 | $55.71 | $140,835 | 387,318 | Dec 1, 2021 |
| Lachey Jennifer | Chief Scientific Officer | Sale | 739 | $58.73 | $43,401 | 90,261 | Nov 10, 2021 |
| Lachey Jennifer | Chief Scientific Officer | Sale | 10,600 | $50.00 | $530,000 | 85,700 | Nov 4, 2021 |
| Knowles Julius | — | Sale | 2,346 | $42.45 | $99,588 | 270,346 | Nov 1, 2021 |
| Knowles Julius | — | Sale | 148 | $37.55 | $5,557 | 290,619 | Oct 20, 2021 |
| Knowles Julius | — | Sale | 2,653 | $40.13 | $106,465 | 446,608 | Oct 15, 2021 |